Maravai LifeSciences (NASDAQ:MRVI) Reaches New 1-Year High – What’s Next?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)’s share price hit a new 52-week high on Wednesday . The company traded as high as $7.59 and last traded at $7.4750, with a volume of 2543436 shares traded. The stock had previously closed at $5.74.

Analysts Set New Price Targets

A number of research analysts recently commented on MRVI shares. Wall Street Zen upgraded Maravai LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday. UBS Group reissued a “reduce” rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Wells Fargo & Company raised their price target on Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $6.00 price objective on shares of Maravai LifeSciences in a report on Friday, May 8th. Finally, Weiss Ratings raised Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 29th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $6.25.

Maravai LifeSciences Stock Performance

The firm has a fifty day simple moving average of $6.10 and a 200-day simple moving average of $4.49. The company has a market cap of $1.86 billion, a PE ratio of -13.82 and a beta of 0.63. The company has a quick ratio of 2.98, a current ratio of 4.05 and a debt-to-equity ratio of 0.49.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.70%. The firm had revenue of $51.44 million during the quarter, compared to the consensus estimate of $48.67 million. On average, research analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.2 EPS for the current fiscal year.

Insider Buying and Selling at Maravai LifeSciences

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total value of $126,500.00. Following the completion of the transaction, the general counsel directly owned 360,767 shares of the company’s stock, valued at $1,825,481.02. This trade represents a 6.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC raised its position in Maravai LifeSciences by 1,463.1% during the first quarter. Jane Street Group LLC now owns 380,403 shares of the company’s stock worth $841,000 after acquiring an additional 356,067 shares during the last quarter. Creative Planning raised its position in shares of Maravai LifeSciences by 49.6% during the 2nd quarter. Creative Planning now owns 116,031 shares of the company’s stock worth $280,000 after purchasing an additional 38,450 shares during the last quarter. Rhumbline Advisers lifted its stake in Maravai LifeSciences by 20.3% in the 2nd quarter. Rhumbline Advisers now owns 195,272 shares of the company’s stock valued at $471,000 after buying an additional 32,940 shares in the last quarter. Prudential Financial Inc. acquired a new stake in Maravai LifeSciences during the 2nd quarter valued at $36,000. Finally, Invesco Ltd. increased its position in Maravai LifeSciences by 16.8% during the second quarter. Invesco Ltd. now owns 282,192 shares of the company’s stock worth $680,000 after buying an additional 40,495 shares in the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.